Literature DB >> 18452219

Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease.

John P Burke1, Marc Ferrante, Karen Dejaegher, R William G Watson, Neil G Docherty, Gert De Hertogh, Severine Vermeire, Paul Rutgeerts, Andre D'Hoore, Freddy Penninckx, Karel Geboes, Gert Van Assche, P Ronan O'Connell.   

Abstract

BACKGROUND: Glucocorticoids and monoclonal antibodies to tumor necrosis factor reduce inflammation in Crohn's disease (CD). Rapid luminal healing, however, may promote intestinal stricture formation. The aim of this study was to examine fibrosis-associated gene expression in the intestine of patients with CD and correlate expression levels with prior medical therapies.
METHODS: In all, 37 patients with stricturing CD and 18 non-CD controls underwent a transmural biopsy at the time of elective intestinal resection. Quantitative real-time polymerase chain reaction (PCR) was conducted to determine differential mRNA expression of TGF-beta(1), Smad-7, CTGF, collagen-1alpha, fibronectin, BMP-7, and MIF. Intestinal fibroblasts were treated in vitro with dexamethasone.
RESULTS: Relative to control, strictured CD intestinal tissue expressed increased TGF-beta(1), CTGF, collagen-1alpha, and BMP-7 (all P < 0.05). TGF-beta(1) gene expression positively correlated with the expression of its downstream targets (all P < 0.001). Preoperative infliximab exposure was not associated with increased expression in any of the target genes nor did the number of infliximab infusions correlate with gene expression. The number of cycles of corticosteroid treatment preoperatively was positively associated with CTGF (r = 0.486, P = 0.016) and MIF (r = 0.524, P = 0.009) expression. Intestinal fibroblasts treated in vitro with dexamethasone upregulated CTGF expression (P = 0.023).
CONCLUSIONS: Exposure to infliximab does not appear to induce a profibrotic transcriptional response in the CD intestine. Previous corticosteroid treatment is associated with increased expression of CTGF and MIF. Treating intestinal fibroblasts in vitro with steroids upregulates CTGF expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452219     DOI: 10.1002/ibd.20482

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

Review 2.  The future of molecular approaches to inflammatory bowel disease.

Authors:  Boyko Kabakchiev; Smita Halder; Mark S Silverberg
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

3.  Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease.

Authors:  Chao Li; Audra Iness; Jennifer Yoon; John R Grider; Karnam S Murthy; John M Kellum; John F Kuemmerle
Journal:  J Immunol       Date:  2015-03-04       Impact factor: 5.422

4.  Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide.

Authors:  Chao Li; Robert S Flynn; John R Grider; Karnam S Murthy; John M Kellum; Homayoon Akbari; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

5.  SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis.

Authors:  Keith W McLarren; Alexandra E Cole; Shelley B Weisser; Nicole S Voglmaier; Victoria S Conlin; Kevan Jacobson; Oana Popescu; Jean-Luc Boucher; Laura M Sly
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

Review 6.  The extracellular matrix in IBD: a dynamic mediator of inflammation.

Authors:  Aaron C Petrey; Carol A de la Motte
Journal:  Curr Opin Gastroenterol       Date:  2017-07       Impact factor: 3.287

Review 7.  Intestinal fibrosis in IBD--a dynamic, multifactorial process.

Authors:  Florian Rieder; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

Review 8.  Mechanisms that mediate the development of fibrosis in patients with Crohn's disease.

Authors:  Chao Li; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 9.  Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology?

Authors:  Florian Rieder; Dominik Bettenworth; Jin Imai; Yutaka Inagaki
Journal:  Inflamm Intest Dis       Date:  2016-03-19

10.  Targeting Gremlin 1 Prevents Intestinal Fibrosis Progression by Inhibiting the Fatty Acid Oxidation of Fibroblast Cells.

Authors:  Yang Yang; Qi-Shan Zeng; Min Zou; Jian Zeng; Jiao Nie; DongFeng Chen; Hua-Tian Gan
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.